BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Down 23.1% in January

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 807,700 shares, a decrease of 23.1% from the December 31st total of 1,050,000 shares. Based on an average daily volume of 801,400 shares, the short-interest ratio is currently 1.0 days.

BioXcel Therapeutics Stock Down 4.0 %

NASDAQ:BTAI opened at $0.33 on Thursday. The stock has a market cap of $16.38 million, a P/E ratio of -0.15 and a beta of -0.01. The business’s 50-day moving average price is $0.40 and its two-hundred day moving average price is $0.60. BioXcel Therapeutics has a twelve month low of $0.30 and a twelve month high of $4.17.

Institutional Investors Weigh In On BioXcel Therapeutics

An institutional investor recently raised its position in BioXcel Therapeutics stock. XTX Topco Ltd raised its stake in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) by 49.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,503 shares of the company’s stock after buying an additional 15,291 shares during the period. XTX Topco Ltd owned about 0.12% of BioXcel Therapeutics worth $60,000 at the end of the most recent quarter. 30.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. Bank of America reaffirmed an “underperform” rating and set a $0.25 target price (down previously from $7.00) on shares of BioXcel Therapeutics in a report on Tuesday, January 7th. Canaccord Genuity Group reduced their price objective on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Finally, HC Wainwright lowered their target price on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, October 21st.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.